NCT05742178 NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
| NCT ID | NCT05742178 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Cancer Screening |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,160 participants |
| Start Date | 2023-07-05 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,160 participants in total. It began in 2023-07-05 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
NYC CONNECT will carry out a randomized controlled trial (RCT) which will assess the relative effectiveness of two evidence-based strategies to increase cancer screening rates for breast, cervical, and colorectal cancer. The RCT will compare the effectiveness of using a combination of 1) culturally and linguistically tailored cancer education materials and 2) community health workers (CHWs) to provide navigation services for cancer screening (the "patient navigation" \[PN\] arm) versus providing culturally and linguistically tailored cancer education only (the "less intensive" \[LI\] arm). The study population will include individuals who are due for breast, cervical, or colorectal cancer screening. All individuals recruited to the study will be provided navigation for unmet social determinants of health (SDH) needs.
Eligibility Criteria
Inclusion Criteria: * Women between the ages of 21 and 75 years; * Men between the ages of 45 and 75 years; * Women (40-74 years) who have not had a mammogram in the past 12 months, a Pap smear in the last 3 years (21-64 years old) or HPV test in the last 5 years (30-64 years old), or women 45-75 years old who are not up-to-date on colorectal cancer screening (Fecal occult blood test (FOBT)/Fecal immunochemical test (FIT) past year, computerized tomography (CT) colonography or sigmoidoscopy past 5 years, or colonoscopy past 10 years); * Men not up-to-date on colorectal cancer screening (FOBT/FIT past year, computerized tomography (CT) colonography or sigmoidoscopy past 5 years, or colonoscopy past 10 years); * Must speak either English, Spanish, Haitian-Creole, French, or Chinese (Mandarin and Cantonese); * Lives in East Flatbush (zip codes: 11236, 11203, 11212, 11226); Sunset Park (zip codes: 11215, 11220, 11232); Highbridge (zip code 10452, 10455, 10451); or Morrisania (zip codes: 10456, 10459) Exclusion Criteria: * Previous or current diagnosis of any cancer; * Pregnancy (breast and cervical cancer only); * Current participation in an existing cancer navigation program; * Currently in hospice care; * At least 66 years of age with advanced illness or frailty or who live in long-term institution for more than 90 days; * Bilateral mastectomy or right and left unilateral mastectomy (breast cancer only); * Hysterectomy with no residual cervix (cervical cancer only); * Total colectomy (colorectal cancer only).
Contact & Investigator
Chau Trinh, PhD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT05742178 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 75 Years, studying Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05742178 currently recruiting?
Yes, NCT05742178 is actively recruiting participants. Contact the research team at chau.trinh@nyulangone.org for enrollment information.
Where is the NCT05742178 trial being conducted?
This trial is being conducted at New York, United States, The Bronx, United States.
Who is sponsoring the NCT05742178 clinical trial?
NCT05742178 is sponsored by NYU Langone Health. The principal investigator is Chau Trinh, PhD at NYU Langone Health. The trial plans to enroll 2,160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.